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Abstract
Despite their clear therapeutic effects in coronary heart disease, use of n-3 polyunsaturated fatty
acids (PUFAs) to treat other types of cardiovascular disease remains controversial, and serious
obstacles exist in implementing them as a reliable and consistent drug therapy. The foremost of these
is that a molecular mechanism and relevant dosages have not been firmly established in other forms
of cardiovascular disease. In this brief review, we highlight the current state of knowledge regarding
the mechanisms behind n-3 PUFA action in the cardiovascular system. We also propose the novel
hypothesis that lipid peroxidation products derived from n-3 PUFAs may be driving much of their
beneficial cardiovascular effects, particularly in the myocardium. We conclude by discussing evidence
to support this hypothesis, and its possible clinical ramifications.
Introduction and context
The enormous impact of cardiovascular disease on global
health and economy demands that low-cost interven-
tions, such as altered lifestyle (e.g. diet and physical
activity), be rigorously implemented for prevention and
treatment. Dietary intake of n-3 PUFAs, particularly fish
oil, is a propitious and therapeutically achievable inter-
vention that has been clearly shown to have a beneficial
effect on the cardiovascular system. However, it is
disappointing that despite significant clinical and experi-
mental research on n-3 PUFAs and cardiovascular disease
over the past 25 years, there is still no clear molecular
mechanism or appropriate dosing strategy in place,
making reliable and consistent therapeutic use of n-3
PUFAs extremely difficult. Thus, a coordinated effort is
needed to establish a mechanism and develop proper
therapeutic paradigms to make n-3 PUFAs more amen-
able for use in prevention and treatment of cardiovascular
disease. Here, we provide a brief overview of the debate
regarding the mechanism of n-3 PUFA therapy among
biomedical researchers, and present a novel hypothesis
that may help reconcile this controversy and unite
existing, well-characterized n-3 PUFA effects with as-yet
unresolved questions.
n-3 PUFA treatment for cardiovascular disease
Existing paradigms and controversy regarding mechanism
Compounds that exert vasodilating, anti-inflammatory,
anti-thrombotic, anti-arrhythmic and heart rate-lowering
effects are all effective therapies for cardiovascular disease.
While n-3 PUFAs have shown promise in virtually all of
these areas, results from clinical trials have been mixed,
with some showing clear benefits and others showing no
change compared with placebo. Excellent comprehensive
reviews of these topics are found in the recent literature
[1,2]. To date, the mechanisms proposed to explain these
beneficial cardiovascular effects have largely focused on
the ability of the two predominant n-3 PUFAs in fish oil,
eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA), to compete with arachidonic acid in the orthodox
pathways of eicosanoid synthesis (Figure 1). Further
support for eicosanoid-mediated n-3 PUFA effects has
come from the discovery of an exciting new family of EPA/
DHA-derived eicosanoids by Serhan and colleagues [3].
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This family of compounds, called the specialized pro-
resolving mediators, exemplified by the ‘resolvin’ series,
were found to have potent properties that enhance the
resolution phase of inflammation, in addition to other
potential therapeutic effects (e.g. analgesia [4]). However,
while the cardiovascular benefits of EPA/DHA-derived
eicosanoidsmust be recognized, burgeoning experimental
evidence suggests that attributing the mechanism of n-3
PUFA therapy in cardiovascular disease solely to eicosa-
noid-mediated effects is grossly over-simplistic.
One of the more intriguing and promising therapeutic
potentials for n-3 PUFAs is in the treatment and
prevention of heart failure [5]. Indeed, fish oil (DHA in
particular) has been shown in several heart failure models
to improve cardiac function and efficiency [6-9]. These
findings have been supported recently by placebo-
controlled clinical trials showing that daily intake of
DHA/EPA for ≥ one year improved left ventricular
function [10] and exercise capacity [11] in patients with
established heart failure. Furthermore, clinically signifi-
cant changes in left ventricular function have been
reported as early as three months after initiating n-3
PUFA treatment [12]. Given that heart failure is known to
result from altered cardiac energetic and structural
parameters, the effects of n-3 PUFAs in enhancing these
parameters has come under vigorous scrutiny by
researchers.
It is clear that n-3 PUFAs are incorporated into membrane
phospholipids in vivo. This is particularly important in
highly oxidative, excitable tissues such as the heart, where
phospholipid composition is critical for propermembrane
structure, thereby ensuring that ion channel activity, charge
separation and energy conservation are maintained.
Several studies have proposed that EPA and DHA directly
modify cardiomyocyte plasma membrane ion channel
activity, which may partially explain their anti-arrhythmic
properties [13-16]. Mitochondria are highly reliant on
cardiolipin, a phospholipid unique to this organelle, to
Figure 1. Pathways of enzymatic and non-enzymatic n-3 PUFA oxidation
The pathway shown in green represents the orthodox enzymatic oxidation cascade that begins with the liberation of EPA or DHA from phospholipids in cellular
membranes by phospholipase A2 (PLA2). The free fatty acid is then acted on by members of the cyclo-oxygenase (COX), 5-lipoxygenase (5-LOX) and
cytochrome P450 monooxygenase (CYP) family of enzymes to form eicosanoids, all of which have various roles in vascular function and innate immunity. The
pathway shown in blue depicts spontaneous oxidation of EPA or DHA by reactive oxygen species, such as superoxide (O2•
-), H2O2 and hydroxyl radical (OH•).
Further oxidation yields lipid peroxides of EPA or DHAwhich, if not neutralized by endogenous antioxidant systems, undergo destabilization and fragmentation
to yield reactive lipids such as isoprostanes, isofuranes, alkenes, alkanes and aldehydes. PG, prostaglandin; TXA, thromboxane; LT, leukotriene.
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maintain membrane electrochemical gradient and capa-
city for oxidative phosphorylation. Recent findings in
animal models of heart failure have demonstrated that
altered cardiolipin structure parallels the increase in
left ventricular function seen with EPA/DHA treatment
[17-19], suggesting that n-3 PUFA incorporation into
cardiolipin may partially explain the improvements in
cardiac function. However, from a biochemical/biophysi-
cal perspective, it is not clear how altering cardiolipin
structure with EPA/DHA incorporation would enhance
mitochondrial function and improve cardiac energetics.
Consequently, alternative metabolic pathways and roles
for n-3 PUFAs in the heart continue to be explored. In
particular, there is compelling evidence that n-3 PUFAs
may play a significant role in gene regulation [20-22],
which may contribute to the many beneficial effects that
have been observed.
Lipoxidative stress from n-3 PUFAs and adaptation in heart
Aside from the well-characterized enzymatic pathways,
PUFAs are prone to oxidation from non-enzymatic (i.e.
spontaneous) reactions because of their highly unsatu-
rated structure. These reactions, initiated by reactive
oxygen and nitrogen species, ultimately form lipoxida-
tive products such as lipid peroxides, reactive aldehydes
and other electrophilic lipids (Figure 1). Of all PUFAs,
DHA is the most susceptible to lipid peroxidation due to
its chemical structure [23]. To date, non-enzymatic
oxidation pathways and lipoxidative products of n-3
PUFAs have been largely ignored by investigators, with a
few exceptions. The reasons for this paucity of investiga-
tion are not completely clear, but could be due to either
the strongly supported belief that the rate of non-
enzymatic n-3 PUFA oxidation in vivo is negligible, or
that the previously held idea that any form of lipid
peroxidation is undesirable as it is unconditionally toxic.
The latter idea has recently been challenged on the basis
of studies described below.
In fact, evidence is accumulating that suggests that PUFA-
derived ‘lipoxidative stress’ can be beneficial in many
contexts, particularly in cells and tissues that are highly
plastic and adaptable, such as the heart. Indeed, it has long
been known that 4-hydroxynonenal, an aldehyde formed
from n-6 PUFA oxidation, exerts bi-directional effects on
the heart, characterized by a beneficial “hormetic” effect at
sub-toxic concentrations (≤10µM), but toxic effects at
higher concentrations [24]. The molecular mediators of
these positive adaptations to “hormetic” concentrations of
4-hydroxynonenal are only beginning to be elucidated,
but recent studies have pointed to the involvement of the
eukaryotic translation initiating factor 2/activating tran-
scription factor-4 (eIF2a/ATF4), NF E2-related factor-2
(Nrf2), and peroxisome proliferator-activated receptor
(PPAR) family of transcription factors in up-regulating
amino acid biosynthesis [25], antioxidant/anti-inflamma-
tory genes [26,27], and mitochondrial biogenesis [28,29],
respectively.
Consistent with this, Gao and co-workers demonstrated
that oxidized derivatives of n-3 PUFAs up-regulate Nrf2
activity in several stable cell lines, in vitro [30]. Whether
similar pathways of adaptation occur in heart as a result
of lipoxidative products formed from n-3 PUFAs remains
to be determined (Figure 2), but a recent study in our
laboratory showed that dietary intake of n-3 PUFAs
resulted in a time-dependent increase in 4-hydroxyhexenal
adducts in the heart and up-regulation of Nrf2-mediated
enzymes in mice that were paralleled by decreased
mitochondrial reactive oxygen species production and
enhanced mitochondrial tolerance to insults such as Ca2+
overload [31]. Several clinical studies have reported
marked increases in antioxidant enzymes such as super-
oxide dismutase, catalase and glutathione peroxidase in
blood of patients taking n-3 PUFAs [32-37] and in some
cases, lipid peroxidation levels increased in parallel with
elevation in these enzymes [38,39]. Furthermore, a
number of studies in animals have reported increased
expression of antioxidant/anti-inflammatory enzymes in
heart following n-3 PUFA diet [40-43], and these were
supported by findings from a small clinical trial showing
that pre-surgical intake of fish oil suppressedNFkB activity
and augmented antioxidant activity in heart tissue of
patients undergoing cardiac surgery [44].
Treating the heart with stress: are lipoxidative products
of n-3 PUFAs mediators of their therapeutic effect?
The context and background provided by the findings
outlined above allude to a provocative question: is it
possible that, to some (or even a large) extent, the cardio-
vascular benefits derived from n-3 PUFAs result from the
‘lipoxidative stress’ that they cause? If so, it would follow
that any physiological state resulting in sustained increases
in cellular and tissue reactive oxygen species (e.g.
cardiovascular and metabolic diseases) would drive
increased lipoxidative product formation when presented
with EPA and DHA. This is undoubtedly a controversial
hypothesis because it contradicts existing paradigms
regarding reactive oxygen species and disease, but we
offer the following evidence in support of this.
First, recent reports demonstrated that oxidized DHA
has the highest affinity and PPAR-activating effect of
any PPAR ligand tested, including all members of the
fibrate and glitazone drug classes [45,46]. This finding
could have broad clinical implications because it
indicates that DHA peroxidation in vivo would greatly
enhance its potency as a PPAR activator. Secondly, an
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interesting study by Judé and colleagues showed that
the electrophysiological effects of DHA on the transient
outward current in cardiomyocytes were only present
when the DHA was oxidized [47]. This finding led the
authors to speculate that perhaps much of the
electrophysiological effects that investigators have
attributed to DHA were actually coming from lipox-
idative products derived from it, since a large amount
Figure 2. Proposed intracellular effects of n-3 PUFA-derived peroxides and reactive aldehydes
Upon entering cells, DHA and EPA are either used for oxidative metabolism (not shown) or esterified and used for phospholipids within membranes (shown
here in both plasma and mitochondrial membranes). Liberation of DHA and EPA from the phospholipids is catalyzed by Phospholipase A2 (PLA2). In their
free fatty acid form, the n-3 PUFAs are oxidized directly by reactive oxygen species coming from sources such as nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase or mitochondrial electron transport system. The lipid peroxides formed in this manner are then more reactive and their potency as
transcriptional activators is increased, as depicted by the hydroperoxy-DHA reacting with PPARs and Nrf2. Sustained increases of these lipid peroxides can
lead to a build-up of their reactive aldehyde derivatives such as 4-hydroxyhexenal and 4-oxo-2-hexenal (OHE), and these can also cause transcriptional
activation or react with functional proteins directly. Activation of PPARs would be expected to cause increased mitochondrial gene expression and lipid
oxidation capacity, particularly in the heart. Nrf2 activation would lead to increased expression of antioxidant/anti-inflammatory genes. Possible outcomes of
the direct protein modifications include changes in ion channel conductance (shown in plasma membrane above) or in altered activity of mitochondrial
respiratory enzymes. Keap1, Kelch-like ECH-associated protein 1; PGC1a, PPARg coactivator-1a; ANT, adenine nucleotide translocase; GST, glutathione
S-transferase; GCLC, g-glutamylcystein ligase catalytic subunit; GR, glutathione reductase; Trx, thioredoxin; Trx-R; thioredoxin reductase.
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of DHA oxidation occurs spontaneously upon expo-
sure to air (~30%).
Asmentioned above, it is now clear that 4-hydroxynonenal
can exert a beneficial effect on the heart. Zhang et al. [26]
recently showed that treating cardiomyocytes with small,
sub-toxic doses (5µM) of 4-hydroxynonenal elicits protec-
tion from subsequent exposure to toxic doses (≥20 µM).
This group further showed the physiological relevance of
this effect by pre-treating mice with 4-hydroxynonenal
prior to ischemia/reperfusion, and showed that 4-hydro-
xynonenal-treated mice exhibited reduced infarct size. In
addition, this 4-hydroxynonenal-induced cardioprotection
was lost in Nrf2 -/- mice, suggesting a fundamental
requirement for Nrf2 in the 4-hydroxynonenal effect
[26]. The role of Nrf2 in cardioprotection is only beginning
to be understood, and this was underscored by a recent
study where overexpression of Nrf2 protected against
Figure 3. Diagram of proposed clinical effects of n-3 PUFA-derived peroxides and reactive aldehydes in heart
Many of the cardiovascular effects of n-3 PUFAs have been linked to their anti-thrombotic, antioxidant/anti-inflammatory, anti-arrhythmic, and vasorelaxing
activities. We propose that many of these effects are mediated by n-3 PUFA-derived peroxides and reactive aldehydes. Moreover, to this list of well-known
clinical effects of n-3 PUFAs we add enhanced mitochondrial biogenesis (i.e. gene expression) and antioxidant capacity in the myocardium, which would be
expected to augment fatty acid oxidation and protect mitochondria against insults such as Ca2+ overload. The latter effects would be expected to have
particular importance in clinical scenarios such as pathological cardiac hypertrophy and heart failure, conditions known to result in, or be a result of,
mitochondrial dysfunction.
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pressure overload-induced cardiac hypertrophy [48].
4-hydroxyhexenal is the n-3 PUFA alkenal equivalent to
4-hydroxynonenal, which is similar in structure but
displays different reactivity. As an electrophile, it is
equipotent in activating Nrf2 [27], but studies on heart
mitochondria in our laboratory have shown that at
physiological concentrations, 4-hydroxynonenal inhibits
oxidative phosphorylation and also causes increased
susceptibility to Ca2+ overload, whereas 4-hydroxyhexenal
does not (unpublished data). From a translational
perspective, this observation is important because it
implies that n-3 PUFA-derived lipoxidative products may
cause similar adaptations to those of n-6 PUFA-derived
lipoxidative products, without as much of the correspond-
ing cellular and mitochondrial toxicity.
Further direction
It must be emphasized that if indeed n-3 PUFA-derived
lipoxidative products are partially responsible for the
therapeutic effects observed, this would be manifested to
the greatest extent in highly plastic and adaptable organs
(i.e. organswith large antioxidant capacities, like the heart).
The reason for this is because 4-hydroxyhexenal, and
indeed all n-3 PUFA-derived lipoxidative products, will
affect tissues and organ systems differently depending on
their ability to positively adapt to mild ‘lipoxidative stress.’
Moreover, it is expected that this adaptation would require
several days or weeks to become optimal. Despite these
considerations, our contention is that when taken together,
the experimental evidence outlined here and elsewhere
[49,50] supports the notion that many of the broad effects
of n-3 PUFAs in cardiovascular disease (Figure 3) can be
explained by lipoxidative products derived from them,
particularly reactive aldehydes such as 4-hydroxyhexenal. If
further investigation confirms this observation, it is
deserving of rigorous evaluation as it may allow for future
development of novel n-3 PUFA therapies in cardiovascular
disease and other diseases, and assist in developing relevant
and proper dosing strategies for n-3 PUFA use in clinics.
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